secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001213900-23-087289
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma Q3 2023 revenue down 62% to $16K; net loss improves 11% to $3.37M
--------------------------------------------------------------------------------

- Q3 2023 revenue $15,884 vs $42,269 in Q3 2022; cash increased to $500K from $85K at year-end 2022.
- Net loss narrowed to $3.37M from $3.78M; operating expenses fell 43% to $2.14M.
- MDD drug ABV-1504 completes Phase II; licensing deal with Xinnovation worth up to $20M for China rights.
- Signed global licensing agreement with AIBL for CNS drugs valued at $667M; ABVC and BioLite to receive 23M AIBL shares at $10/share plus milestones.
- Regained Nasdaq minimum bid price compliance; shareholders' equity at $9.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/0001213900-23-087289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/ea188352-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-087289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer